سولفاسالازین خوراکی در درمان بیماران آلوپسی آرهآتای مقاوم به درمان
Authors
Abstract:
Background and Aim: Alopecia Areata is a chronic inflammatory disease which involves hair follicles. The aim of this study was to assess the efficacy of oral sulfasalazine in the treatment of recalcitrant alopecia areata.Methods: Patients with refractory alopecia areata who were eligible for the study, after providing informed consent were treated with oral sulfasalazine for 6 months. After completion of treatment, regrowth of vellus and terminal hairs were determined based on clinical examination and comparing the new photographs with the baseline ones.Results: Sixteen patients were enrolled in the present study but only 5 patients completed it. No response was seen in 3 patients. After 4 months, 55-60% response to treatment was observed in 1 patient, but the disease relapsed at the end of fourth month. In 1 patient, 15% hair regrowth was observed but treatment was discontinued after the second month due to side effects. Side effects were observed in 2 patients.Conclusion: Since only refractory alopecia areata patients had been enrolled to the study, the results could not be generalized to all patients with alopecia areata. Therapeutic response in the patients with alopecia areata is disappointing and any poor treatment response or failure of treatment in refractory cases of the disease cannot rule out the efficacy of the drug in the milder forms of the alopecia areata.
similar resources
سولفاسالازین خوراکی در درمان بیماران آلوپسی آره آتای مقاوم به درمان
زمینه و هدف: آلوپسی آره آتا بیماری التهابی مزمن است که با درگیری فولیکول های مو همراه است. هدف از این مطالعه بررسی پاسخ اثرات سولفاسالازین در درمان بیماران آلوپسی آره آتای مقاوم به درمان می باشد.روش کار: بیماران آلوپسی آره آتای مقاوم به درمان دارای شرایط لازم جهت ورود به مطالعه، با اخذ رضایت نامه ی آگاهانه به مدت 6 ماه تحت درمان با سولفاسالازین قرار گرفتند. پس از اتمام دوره ی درمان، رشد مجدد مو...
full textمقایسه تأثیر وضعیت طاق باز و دمر بر وضعیت تنفسی نوزادان نارس مبتلا به سندرم دیسترس تنفسی حاد تحت درمان با پروتکل Insure
کچ ی هد پ ی ش مز ی هن ه و فد : ساسا د مردنس رد نامرد ي سفنت سرتس ي ظنت نادازون داح ي سکا لدابت م ي و نژ د ي سکا ي د هدوب نبرک تسا طسوت هک کبس اـه ي ناـمرد ي فلتخم ي هلمجزا لکتورپ INSURE ماجنا م ي دوش ا اذل . ي هعلاطم ن فدهاب اقم ي هس عضو ي ت اه ي ندب ي عضو رب رمد و زاب قاط ي سفنت ت ي هـب لاتـبم سراـن نادازون ردنس د م ي سفنت سرتس ي لکتورپ اب نامرد تحت داح INSURE ماجنا درگ ...
full textبررسی پاسخ به درمان با آرسنیک تریاکسید در بیماران میلوم متعدد مقاوم به درمان
Normal 0 false false false EN-US X-NONE AR-SA MicrosoftInternetExplorer4 /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal" mso-tsty...
full textاثربخشی مایکوفنولات موفتیل در درمان بیماران مبتلا به پمفیگوس ولگاریس مقاوم به درمان
Background and Aim: Pemphigus is one of the most common types of autoimmune blistering disease that requires systemic immunosuppressive therapy. Immunosuppressive therapy has improved the disease outcome in recent decades, but long-term use of them has side effects. Recently, it has been tried to evaluate immunosuppressive drugs with less side effects. One of them is mycophenolate mofetil. The ...
full textنوروکتومی پره ساکرال درمان امیدبخش در بیماران اندومتریوزیس با درد مقاوم به درمان
Endometriosis is a painful chronic disorder in premenopausal period that causes severe pelvic pain. It could be problematic for both the patient and physician since routine analgesic drugs may not resolve the symptoms. Therefore, various destructive surgical treatments are used in these patients and presacral neurectomy is one of the best and most recommended surgical methods. This paper report...
full textاثر سیکلوسپورین روی بیماران پمفیگوس مقاوم به درمان های کلاسیک
Pemphigus is a chronic blistering disease and prednisolone is regarded as the treatment of choice for this disease. The doses of prednisolone required are high, and considerable morbidity maybe associated the treatment. Immunosuppressive drugs, particularly azathioprin are frequently used addition to prednisolone, as steroid – sparing agents, although in our experience, these are not...
full textMy Resources
Journal title
volume 4 issue 2
pages 84- 91
publication date 2013-06
By following a journal you will be notified via email when a new issue of this journal is published.
No Keywords
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023